Financial Performance - The company's operating revenue for Q3 2024 reached ¥86,777,991.20, representing a year-on-year increase of 21.41%[2] - Net profit attributable to shareholders was ¥27,921,006.76, reflecting a growth of 10.95% compared to the same period last year[2] - Basic earnings per share (EPS) for the quarter was ¥0.34, a rise of 9.68% year-on-year[2] - Total operating revenue for the first three quarters of 2024 reached ¥240,117,907.83, an increase of 16.2% compared to ¥206,601,313.31 in the same period of 2023[18] - Operating profit for the first three quarters of 2024 was ¥91,974,599.66, up from ¥76,816,522.05 in 2023, reflecting a growth of 19.3%[18] - Net profit attributable to shareholders of the parent company for the first three quarters of 2024 was ¥76,713,229.82, compared to ¥64,346,824.69 in 2023, marking an increase of 19.5%[19] - The company reported a total profit of ¥92,332,439.71 for the first three quarters of 2024, compared to ¥77,054,382.41 in 2023, an increase of 19.7%[19] - The company recorded a net profit margin of approximately 31.6% for the first three quarters of 2024, compared to 30.8% in the same period of 2023[19] Cash Flow and Investments - The net cash flow from operating activities amounted to ¥33,736,059.15, with a significant increase of 69.37% year-to-date[8] - In the first three quarters of 2024, the company generated operating cash inflow of CNY 288,963,805.42, an increase of 14.9% compared to CNY 251,458,415.59 in the same period of 2023[21] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 109,654,732.43, up from CNY 64,742,464.57 in 2023, representing a significant increase of 69.2%[22] - The company reported a total cash outflow from investing activities of CNY 498,816,423.88 in 2024, a decrease from CNY 700,533,529.94 in 2023, indicating a reduction of 28.8%[22] - The company incurred a net cash outflow from financing activities of CNY 29,942,653.10 in Q3 2024, slightly improved from CNY 30,628,196.86 in Q3 2023[22] - The cash inflow from investment activities in Q3 2024 was CNY 347,020,186.10, down from CNY 551,616,423.99 in Q3 2023, a decrease of 37.0%[22] - The company reported a cash outflow of CNY 420,000,000.00 related to investment activities in Q3 2024, down from CNY 674,500,000.00 in Q3 2023, indicating a decrease of 37.7%[22] Research and Development - Research and development (R&D) expenses totaled ¥8,183,154.79 for the quarter, marking a 49.90% increase, attributed to projects entering clinical trial phases[8] - The proportion of R&D expenses to operating revenue was 9.43%, an increase of 1.79 percentage points compared to the same period last year[4] - Research and development expenses for the first three quarters of 2024 amounted to ¥16,399,769.03, up from ¥13,734,653.11 in 2023, indicating a growth of 19.4%[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥737,663,275.58, up 9.16% from the end of the previous year[4] - The company's total current assets as of September 30, 2024, amount to RMB 417,813,421.07, a decrease from RMB 426,650,740.33 at the end of 2023[14] - The total non-current assets increased to RMB 319,849,854.51 from RMB 249,136,662.79 in the previous year[15] - The total liabilities increased to ¥96,906,684.48 in Q3 2024 from ¥90,277,053.85 in Q3 2023, representing an increase of 7.1%[18] - Accounts payable increased to RMB 26,968,968.48 from RMB 16,844,707.96, indicating a rise of approximately 60.5%[15] Shareholder Information - Shareholders' equity attributable to the parent company reached ¥638,401,914.54, reflecting an 8.72% increase from the previous year[4] - The total equity attributable to shareholders of the parent company increased to ¥638,401,914.54 in Q3 2024 from ¥587,184,063.37 in Q3 2023, a rise of 8.7%[18] - The total number of common shareholders at the end of the reporting period is 81,200, with the top 10 shareholders holding 77.67% of the shares[10] - The largest shareholder, Hu Liren, holds 39,545,788 shares, representing 48.68% of the total shares[10] Employee Compensation - The company paid CNY 58,452,631.10 in employee compensation in the first three quarters of 2024, an increase of 13.5% from CNY 51,616,821.83 in the same period of 2023[21]

本次获批的基台及附件包括：覆盖螺帽、愈合基台、临时基台和基台、种植 体配套用螺钉。该产品为公司在研的"高端骨结合种植体及附件产品开发"项目 中的部分产品，采用符合 GB/T 13810 标准的纯钛（TA4G）及钛合金（TC4）材 料制成，连接方式采用梅花和八方连接，通过连接结构的一致性及抗旋等设计， 提高产品适配性，使其具有更为便捷的操作性。本次产品获批进一步丰富公司口 腔业务产品线，将加速公司新一代锥形种植体和即刻种植体系列产品的整体上市 进度。 证券代码：688314 证券简称：康拓医疗 公告编号：2024-025 西安康拓医疗技术股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 西安康拓医疗技术股份有限公司（以下简称"公司"）于近日取得国家药品 监督管理局颁发的第三类《医疗器械注册证》，具体情况如下： | 注册人名称 | 西安康拓医疗技术股份有限公司 | | --- | --- | | 产品名称 | 基台及附件 | | 适用范围/预期用途 | 用于连接、支持和固位修复 ...

华泰联合证券有限责任公司 关于西安康拓医疗技术股份有限公司 2024 年半年度持续督导跟踪报告 | 保荐机构名称：华泰联合证券有限责任公司 | 被保荐公司名称：西安康拓医疗技术股份有限 | | --- | --- | | | 公司 | | 保荐代表人姓名：郑明欣 | 联系电话：010-56839300 | | 保荐代表人姓名：丁明明 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科创 板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以下简 称"华泰联合证券"或"保荐机构"）作为西安康拓医疗技术股份有限公司（以下简称 "康拓医疗"、"公司"或"发行人"）首次公开发行股票的保荐机构，对康拓医疗进行 持续督导，并出具 2024 年半年度（以下简称"本报告期"或"报告期"）持续督导 跟踪报告： 序号 项目 持续督导工作情况 1 建立健全并有效执行持续督导工作制 度，并针对具体的持续督导工作制定 相应的工作计划。 保荐机构已制定并严格执行持续督导 工作制度，已根据公司的具体情况制 定了相应的工作计划。 2 根据中国证监会相关规定，在持续督 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2024-024 西安康拓医疗技术股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 西安康拓医疗技术股份有限公司（以下简称"公司"）于近日取得国家药品 监督管理局颁发的第三类《医疗器械注册证》，具体情况如下： | 注册人名称 | 西安康拓医疗技术股份有限公司 | | --- | --- | | 产品名称 | 聚醚醚酮颅骨固定系统 | | 适用范围/预期用途 | 适用于颅骨骨折内固定和缺损部位固定 | | 注册证编号 | 国械注准 20243131607 | | 类别管理 | 第三类 | | 有效期至 | 2029 年 8 月 26 日 | 一、医疗器械注册证具体情况 三、风险提示 1 上述产品获批后的入院销售尚需履行相关院内审批、招标、挂网等前置程序， 其未来业绩受市场拓展力度及市场实际需求多重因素影响，产品销售及利润贡献 具有不确定性，尚无法预测其对公司未来业绩的具体影响。 敬请广大投资者谨慎投资、注意投资风险。 特此 ...

Group 1: Product Development and Market Competitiveness - The new generation of high-end bone-integrated implants is expected to complete product registration within this year, significantly enhancing the company's market competitiveness in the oral field [1][2] - The product features hydrophilic sandblasting and acid washing surface treatment to increase bone integration strength, improving adaptability and stability for different bone conditions [2][3] Group 2: Financial Performance - Revenue from other products increased from 9 million to 16 million, a growth of 700 thousand, with 330 thousand attributed to the PEEK material sternum fixation belt [3] - The increase in revenue also includes contributions from maxillofacial repair products and supporting surgical tools [3]

Financial Performance - The company achieved a revenue of CNY 153.34 million in the first half of 2024, representing a year-on-year growth of 13.48% [4] - The net profit attributable to shareholders was CNY 48.79 million, an increase of 24.53% compared to the same period last year [4] - The net profit after deducting non-recurring gains and losses was CNY 40.30 million, up by 7.35% year-on-year [5] Business Segments - Neurosurgery business generated revenue of CNY 133.06 million, with a year-on-year growth of 7.97%. PEEK material products contributed CNY 96.22 million, growing by 15.45% and accounting for 65.10% of the main business revenue [5] - The cardiothoracic surgery segment reported revenue of CNY 9.84 million, with PEEK material chest fixation products achieving sales of CNY 9.74 million, a significant increase of 51.53% [5] Market Expansion - The company successfully implemented the Henan Provincial Alliance neurosurgery centralized procurement in Q2 2024, leading to increased penetration of PEEK material products [6] - In the first half of 2024, overseas revenue reached CNY 16.22 million, a growth of 14.97% year-on-year, with the overseas subsidiary BIOPLATE generating CNY 15.03 million, up by 18.53% [8] Product Development - The company is actively expanding its jaw repair business, leveraging academic training and partnerships with experts to enhance market recognition and application [7] - The introduction of the new generation "high-end bone integration implants and accessories" is in the product registration phase, expected to enhance market competitiveness in the dental field [10] Innovation and Future Strategy - The innovative product "3D printed PEEK cranial system" has been successfully applied in multiple surgeries, demonstrating its superior performance and accelerating the commercialization of innovative technologies [10] - The company plans to continue expanding its high-value non-centralized procurement products and optimize production processes to maintain stable gross margins [6]

Summary of the Conference Call for 康托医疗 Company Overview - 康托医疗 specializes in three categories of medical devices, primarily focusing on neurosurgery and repair fields [1] Key Points and Arguments - The company is set to discuss its mid-year performance for 2024, indicating a focus on financial results and operational metrics [1] - The management, represented by the Secretary of the Board, emphasizes the importance of understanding the basic situation of the mid-year report [1] Additional Important Content - The call highlights the company's commitment to providing insights into its performance, which may include revenue figures, market share, and growth strategies in the medical device sector [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported revenue of 153 million yuan for H1 2024, representing a year-over-year increase of 13.48%, and a net profit of 49 million yuan, up 24.53% year-over-year. In Q2 2024, revenue reached 83 million yuan, a year-over-year increase of 18.36%, with net profit at 29 million yuan, up 46.04% year-over-year [2][3] - The company is actively adjusting its business strategy to enhance product penetration and accelerate product admission into hospitals, particularly in lower-tier markets, contributing to steady revenue growth [2] - The gross margin for H1 2024 was 80.10%, a decrease of 0.98 percentage points, while the net margin increased by 2.93 percentage points to 31.48% [2] - The company has adjusted its profit forecasts for 2024-2026, expecting net profits of 90 million, 113 million, and 141 million yuan respectively, with corresponding EPS of 1.11, 1.39, and 1.73 yuan, leading to P/E ratios of 16.9, 13.5, and 10.8 times [2][3] Summary by Sections Financial Performance - H1 2024 revenue was 153 million yuan, with a year-over-year growth of 13.48% - Net profit for H1 2024 was 49 million yuan, reflecting a year-over-year increase of 24.53% - Q2 2024 revenue was 83 million yuan, up 18.36% year-over-year, and net profit was 29 million yuan, up 46.04% year-over-year [2][3] Product Performance - PEEK neurosurgical products generated revenue of 96 million yuan, a year-over-year increase of 15.45%, with a gross margin of 84.86% - The penetration rate for PEEK cranial repair products was approximately 13.59%, indicating significant growth potential in the industry [2] - PEEK sternal fixation strips achieved revenue of 974 thousand yuan, growing by 52%, with substantial market potential [2] R&D and Market Expansion - The company is expanding its product offerings and enhancing R&D efforts, including local production of PEEK plates in the U.S. and advancing the registration of new products in China [2] - The company is also focusing on comprehensive solutions in the dental sector through its "Yizhi" brand, which includes a range of dental products [2]

证券代码：688314 证券简称：康拓医疗 公告编号：2024-022 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会出具的《关于同意西安康拓医疗技术股份有限公 司首次公开发行股票注册的批复》（证监许可[2021]959 号）核准，并经上海证券 交易所同意，公司首次公开发行人民币普通股（A 股）1,451.00 万股。募集资金 总额为人民币251,603,400.00元，扣除不含税的发行费用人民币43,355,571.58元， 募集资金净额为人民币 208,247,828.42 元。本次募集资金已于 2021 年 5 月 13 日 全部到位，中审众环会计师事务所（特殊普通合伙）于 2021 年 5 月 13 日对资金 到位情况进行了审验，并出具了《验资报告》（众环验字[2021] 0800005 号）。 公司已按照相关规定对募集资金采取了专户存储管理，并与保荐机构、募集 资金专户监管银行签订了募集资金三方监管协议。 （二）2024 年半年度（或"报告期"）募集资金使用金额及期末余额 截至 2024 年 6 月 30 日，公司累计使用募集资金 205,867,006.66 元，2024 年 上半 ...

关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688314 证券简称：康拓医疗 公告编号：2024-023 西安康拓医疗技术股份有限公司 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 08 月 15 日(星期四)至 08 月 21 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2024 年 8 月 14 日发布公司 2024 年半年度报告，为便于广大投资者更全面深入地了解公司 2024 年半年度经营成果、财务状况，公司计划于 2024 年 08 月 22 日下午 16:00-17:00 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半年度的经营 成果 ...